Sorry Rappers, page-119

When the term "Compelling clinical evidence" is stated in every investor presentation, it is an assumption that this clinical evidence is based from a trial. When ResApp spend millions of dollars in Australia, you would assume the data collected would would account for at minimum a domestic approval.

I actually asked management earlier in the year around domestic approvals, the response was ResApp are dedicating their resources entirely to the US study. Now after these results, they are investigating CE and TGA marking, but it will require another domestic trial and patients from scratch.

The fact is the algorithm for the past two years has been trained on data sets the TGA would not even accept as its not blinded or conducted independently.

I still walk away from this investment well in a profit, not what I was dreaming of but nevertheless no emotions here.